Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan disease

European Journal of Paediatric Neurology

Volumn 14, Issue 4, 2010, Pages 354-359

  Assadi, Mitra ^a   Janson, Christopher ^b   Wang, Dah Jyuu ^c   Goldfarb, Olga ^a   Suri, Neeti ^c   Bilaniuk, Larissa ^c   Leone, Paola ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Canavan disease; Lithium; NAA

Indexed keywords

LITHIUM CITRATE; N ACETYLASPARTIC ACID;

ALERTNESS; ARTICLE; BASAL GANGLION; CANAVAN DISEASE; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CORPUS CALLOSUM; DIFFUSION TENSOR IMAGING; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; GENETIC ANALYSIS; GROSS MOTOR FUNCTION CLASSIFICATION SYSTEM; HUMAN; INFANT; KIDNEY DISEASE; LABORATORY DIAGNOSIS; LIVER DISEASE; MOTOR DEVELOPMENT; MYELINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRESCHOOL CHILD; PRIORITY JOURNAL; SOCIAL INTERACTION; THERAPY EFFECT; WHITE MATTER;

ASPARTIC ACID; BASAL GANGLIA; CANAVAN DISEASE; CEREBRAL CORTEX; CHOLINE; CITRATES; CREATINE; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; SEVERITY OF ILLNESS INDEX;

EID: 77953230252     PISSN: 10903798     EISSN: 15322130     Source Type: Journal    
DOI: 10.1016/j.ejpn.2009.11.006     Document Type: Article

References (39)

1. Matalon R., and Michals-Matalon K. Molecular basis of Canavan disease. Eur J Paediatr Neurol 2 (1998) 69-76
2. Clark J.B. N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Dev Neurosci 20 (1998) 271-276
3. Janson C.G., McPhee S.W.J., Francis J., Shera D., Assadi M., Freese A., et al. Natural history of Canavan disease revealed by proton magnetic resonance spectroscopy (1H-MRS) and diffusion-weighted MRI. Neuropediatrics 37 (2006) 209-221
4. Kitada K., Akimitsu T., Shigematsu Y., Kondo A., Maihara T., Yokoi N., et al. Accumulation of N-acetyl-L-aspartate in the brain of the tremor rat, a mutant exhibiting absence-like seizure and spongiform degeneration in the central nervous system. J Neurochem 74 6 (2000) 2512-2519
5. Namboodiri M.A.A., Peethambaran A., Mathew R., Sambhu P.A., Hershfield J., Moffett J.R., et al. Canavan disease and the role of N-acetylaspartate in myelin synthesis. Mol Cell Endocrinol. 252 1-2 (2006 Jun 27) 216-223 2006
6. Pederzolli C.D., Rockenbach F.J., Zanin F.R., Henn N.T., Romagna E.C., Sgaravatti A.M., et al. Intracerebroventricular administration of N-acetylaspartic acid impairs antioxidant defenses and promotes protein oxidation in cerebral cortex of rats. Metab Brain Dis (2009 Mar 18) [Epub ahead of print]
7. O'Donnell T., Rozinger S., Nakashima T.T., Hanstock C.C., Ulrich M., and Silverstone P.H. Chronic lithium and sodium valproate both decrease the concentration of myo-inositol and increase the concentration of inositol monophosphates in rat brain. Brain Res 880 (2000) 84-91
8. Baslow M.H., Kitada K., Suckow R.F., Basalingappa L.H., and Serikawa T. The effects of lithium chloride and other substances on levels of brain N-acetyl-L-aspartic acid in Canavan disease-like rats. Neurochem Res 27 5 (2002) 403-406
9. Kessing L.V., Søndergård L., Forman J.L., and Andersen P.K. Lithium treatment and risk of dementia. Arch Gen Psychiatry 65 11 (2008) 1331-1335 2008
10. Leyhe T., Eschweiler G.W., Stransky E., Gasser T., Annas P., Basun H., et al. Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease. J Alzheimers Dis 16 3 (2009) 649-656 2009
11. Nunes P.V., Forlenza O.V., and Gattaz W.F. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry 2007 190 (2007) 359-360
12. Janson C.G., Assadi M., Francis J., Bilaniuk L., Shera D., and Leone P. Lithium citrate for Canavan disease. Pediatr Neurol 33 4 (2005) 235-243
13. Lam W.W.M., Wang Z.J., Zhao H., Berry G.T., Kaplan P., Gibson J., et al. 1H MR spectroscopy of the basal ganglia in childhood: a semiquantitative analysis. Neuroradiology 40 (1998) 315-323
14. Janson C.G., McPhee S.W.J., Bilaniuk L., Haselgrove J., Testaiuti M., Freese A., et al. Clinical protocol. Gene therapy of Canavan disease: aAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther 13 11 (2002 Jul 20) 1391-1412 2002
15. Barkovich A.J., Kjos B.O., Jackson D.E.J., and Norman D. Normal maturation of the neonatal and infant brain: MR imaging at 1.5 T1. Radiology 166 (1988) 173-180
16. Steen R.G., Ogg R.J., Reddick W.E., and Kingsley P.B. Age-related changes in the pediatric brain: quantitative MR evidence of maturational changes during adolescence. AJNR Am J Neuroradiol 18 (1997) 819-828
17. Westbrook G.L., Mayer M.L., Namboodiri M.A.A., and Neale J.H. High concentrations of N-acetylasparylglutamate (NAAG) selectively activiate NMDA receptors on mouse spinal cord neurons in cell culture. J Neurosci 6 11 (Nov 1986) 3385-3392 1986
18. Rubin Y., LaPlaca M.C., Smith D.H., Thibault L.E., and Lenkinski R.E. The effect of N-acetylaspartate on the intracellular free calcium concentration in NTera2-neurons. Neuroendocrinol Lett 198 (1995) 209-212 1995
19. Yan H.-D., Ishihara K., Serikawa T., and Sasa M. Activation by N-acetyl-L-aspartate of acutely dissociated hippocampal neurons in rate via metabotropic glutamate receptors. Epilepsia 44 9 (2003) 1153-1159 2003
20. Pliss L., FitzGibbon T., Balcar V., and Št'astný F. Neurotoxicity of NAAG in vivo is sensitive to NMDA antagonists and mGluR II ligands. Neuropharmacology and Neurotoxicology 11 16 (Nov 2000) 3651-3654 2000
21. Akimitsu T., Kurisu K., Hanaya R., Lida K., Kiura Y., Arita K., et al. Epileptic seizures induced by N-acetyl-L-aspartate in rats: in vivo and in vitro studies. Brain Res 861 1 (2000) 143-150
22. Zaczek R., Koller K., Cotter R., Heller D., and Coyle J. N-acetylaspartylglutamate: an endogenous peptide with high affinity for a brain "glutamate" receptor. Proc Natl Acad Sci USA 80 (Feb 1983) 1116-1119 1983
23. Tranberg M., and Sandberg M. N-Acetylaspartate monomethyl ester increases N-acetylaspartate concentration in cultured rat hippocampal slices: effects of excitotoxicity and levels of amino acids and chloride. J Neurosci Methods 163 (2007) 105-110 2007
24. Taylor D.L., Davies S.E.C., Obrenovitch T.P., Doheny M.H., Patsalos P.N., Clark J.B., et al. Investigation into the role of N-acetylaspartate in cerebral osmoregulation. J Neurochem 65 1 (1995) 275-281
25. Baslow M.H. Brain N-acetylaspartate as a molecular water pump and its role in the etiology of Canavan disease. J Mol Neurosci 21 (2003) 185-189
26. Chuang D. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases?. Crit Rev Neurobiol 16 1-2 (2004) 83-90
27. Hashimoto R., Hough C., Nakazawa T., Yamamoto T., and Chuang D. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 80 (2002) 589-597
28. Nonaka S., Hough C., and Chuang D. Chronic lithium treatment robustly protects neurons in the central nervous system against exitotoxicity by inhibiting N-methy-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci USA 95 5 (1998) 2642-2647
29. Chalecka-Franaszek E., and Chuang D. Lithium activates the serine/threonine kinase Akt-1 and supresses the glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci USA 96 (1999) 8745-8750
30. Chen R.W., and Chuang D. Long term lithium treatment supresses p53 and Bax expression but increases Bcl-2 expression. J Biol Chem 274 10 (1999) 6039-6042
31. Rowe M.K., and Chuang D.-M. Lithium neuroprotection: molecular mechanisms and clinical implications. Expert Rev Mol Med 6 21 (2004) 1-18
32. Moore G.J., Bebchuk J.M., Hasanat K., Chen G., Seraji-Bozorgzad N., Wilds I.B., et al. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects?. Biol Psychiatry 48 (2000) 1-8
33. Silverstone P.H., Wu R.H., O'Donnell T., Ulrich M., Asghar S.J., and Hanstock C.C. Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients. Int Clin Psychopharmacol 18 2 (2003) 73-79
34. Monkul E.S., Matsuo K., Nicoletti M.A., Dierschke N., Hatch J.P., Dalwani M., et al. Prefrontal gray matter increases in healthy individuals after lithium treatment: a voxel-based morphometry study. Neurosci Lett 429 1 (2007) 7-11
35. Brambilla P., Stanley J.A., Sassi R.B., Nicoletti M.A., Mallinger A.G., Keshavan M.S., et al. HMRS study of dorsolateral prefrontal cortex in healthy individuals before and after lithium administration. Neuropsychopharmacology 29 (2004) 1918-1924 2004
36. Fujita T., Katsukawa H., Yodoya E., Wada M., Shimada A., Okada N., et al. Transport characteristics of N-acetyl-L-aspartate in rat astrocytes: involvement of sodium-coupled high-affinity carboxylate transporter NaC3/NaDC3-mediated transport system. J Neurochem 93 (2005) 706-714 2005
37. Sager T.N., Thomsen C., Valsborg J.S., Laursen H., and Hansen A.J. Astroglia contain a specific transport mechanism for N-Acetyl-L-Aspartate. J Neurochem 73 2 (1999) 807-811 1999
38. + -dependent high-affinity dicarboxylate transporter. Am J Physiol, Cell Physiol 278 (2000) 2000C1019-C30
39. Kekuda R., Wang H., Huang W., Pajor A., Leibach F., Devoe L., et al. Primary structure and functional characteristics of a mammalian sodium-coupled high affinity dicarboxylate transporter. J Biol Chem 274 6 (Feb 1999) 3422-3429 1999